RS56721B1 - Piperidinil-indolni derivati kao inhibitori faktora b komplementa i njihova upotreba - Google Patents

Piperidinil-indolni derivati kao inhibitori faktora b komplementa i njihova upotreba

Info

Publication number
RS56721B1
RS56721B1 RS20171318A RSP20171318A RS56721B1 RS 56721 B1 RS56721 B1 RS 56721B1 RS 20171318 A RS20171318 A RS 20171318A RS P20171318 A RSP20171318 A RS P20171318A RS 56721 B1 RS56721 B1 RS 56721B1
Authority
RS
Serbia
Prior art keywords
methyl
indol
methoxy
piperidin
dimethyl
Prior art date
Application number
RS20171318A
Other languages
English (en)
Serbian (sr)
Inventor
Christopher Adams
Michael Paul Capparelli
Takeru Ehara
Rajeshri Ganesh Karki
Nello Mainolfi
Chun Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51230246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56721(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS56721B1 publication Critical patent/RS56721B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20171318A 2013-07-15 2014-07-14 Piperidinil-indolni derivati kao inhibitori faktora b komplementa i njihova upotreba RS56721B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361846355P 2013-07-15 2013-07-15
US201461977028P 2014-04-08 2014-04-08
EP14744744.5A EP3022192B1 (en) 2013-07-15 2014-07-14 Piperidinyl indole derivatives and their use as complement factor b inhibitors
PCT/US2014/046515 WO2015009616A1 (en) 2013-07-15 2014-07-14 Piperidinyl indole derivatives and their use as complement factor b inhibitors

Publications (1)

Publication Number Publication Date
RS56721B1 true RS56721B1 (sr) 2018-03-30

Family

ID=51230246

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171318A RS56721B1 (sr) 2013-07-15 2014-07-14 Piperidinil-indolni derivati kao inhibitori faktora b komplementa i njihova upotreba

Country Status (40)

Country Link
US (2) US9682968B2 (enExample)
EP (2) EP3022192B1 (enExample)
JP (1) JP6378761B2 (enExample)
KR (1) KR102242742B1 (enExample)
CN (1) CN105579444B (enExample)
AP (1) AP2016008992A0 (enExample)
AU (1) AU2014290298B2 (enExample)
BR (1) BR112016000909B1 (enExample)
CA (1) CA2917839C (enExample)
CL (1) CL2016000060A1 (enExample)
CU (1) CU24397B1 (enExample)
CY (2) CY1119767T1 (enExample)
DK (1) DK3022192T3 (enExample)
EA (1) EA031030B1 (enExample)
ES (1) ES2655855T4 (enExample)
FI (1) FIC20240032I1 (enExample)
FR (1) FR24C1036I2 (enExample)
GT (1) GT201600007A (enExample)
HR (1) HRP20172000T1 (enExample)
HU (2) HUE037510T2 (enExample)
IL (2) IL243540B (enExample)
JO (1) JO3425B1 (enExample)
LT (2) LT3022192T (enExample)
MX (1) MX351291B (enExample)
MY (2) MY187454A (enExample)
NL (1) NL301292I2 (enExample)
NO (1) NO2024042I1 (enExample)
PE (1) PE20161066A1 (enExample)
PH (1) PH12016500072B1 (enExample)
PL (1) PL3022192T3 (enExample)
PT (1) PT3022192T (enExample)
RS (1) RS56721B1 (enExample)
SG (1) SG11201600086PA (enExample)
SI (1) SI3022192T1 (enExample)
SV (1) SV2016005137A (enExample)
TN (1) TN2016000017A1 (enExample)
TW (1) TWI641600B (enExample)
UA (1) UA117371C2 (enExample)
UY (1) UY35663A (enExample)
WO (1) WO2015009616A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
CA3027500A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3939591A1 (en) * 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN113444047B (zh) * 2016-07-20 2023-06-16 纳莹(上海)生物科技有限公司 一种荧光探针及其制备方法和用途
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
RS65380B1 (sr) 2017-08-24 2024-04-30 Novo Nordisk As Glp-1 kompozicije i njihova upotreba
EP4647121A2 (en) * 2017-08-31 2025-11-12 Novartis AG Novel uses of piperidinyl-indole derivatives
WO2020016749A2 (en) 2018-07-16 2020-01-23 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
WO2020144604A1 (en) 2019-01-11 2020-07-16 Novartis Ag Lta4h inhibitors for the treatment of hidradenitis suppurativa
US12435150B2 (en) 2019-01-11 2025-10-07 Novartis Ag Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa
CN115135304A (zh) 2020-02-18 2022-09-30 诺和诺德股份有限公司 Glp-1组合物及其用途
WO2021168320A1 (en) 2020-02-20 2021-08-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
TW202504893A (zh) * 2020-05-18 2025-02-01 瑞士商諾華公司 Lnp023之結晶形式
JP7293513B2 (ja) 2020-07-16 2023-06-19 ノバルティス アーゲー Ｂ因子阻害剤の使用方法
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
EP4194449A4 (en) * 2020-08-07 2024-03-20 Shanghai Meiyue Biotech Development Co., Ltd. Heterocyclic compound, preparation method therefor and use thereof
BR112023001195A2 (pt) * 2020-08-07 2023-02-28 Shanghai Meiyue Biotech Dev Co Ltd Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto
EP4216946A4 (en) 2020-09-23 2024-11-13 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
AU2021414253B2 (en) * 2020-12-30 2024-05-16 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Series of piperidine-substituted benzoic acid compounds, and use thereof
CA3203320A1 (en) * 2020-12-30 2022-07-07 Xin Li Nitrogen-containing bridged heterocyclic compound, preparation method therefor, and medical use thereof
CA3205097A1 (en) * 2021-01-14 2022-07-21 Jason Allan Wiles Macrocycle complement factor b inhibitors
US20240217953A1 (en) * 2021-04-16 2024-07-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic substituted aromatic carboxylic acid compounds
KR20240004947A (ko) * 2021-05-07 2024-01-11 노파르티스 아게 비정형 용혈성 요독 증후군 치료용 입타코판
BR112023025235A2 (pt) * 2021-06-03 2024-02-27 Chinook Therapeutics Inc Compostos de indol substituídos e métodos de uso dos mesmos
JP2024522769A (ja) 2021-06-18 2024-06-21 ノバルティス アーゲー 自己免疫性血液学的疾患を治療する方法
EP4362933A4 (en) * 2021-06-30 2025-06-04 Apellis Pharmaceuticals, Inc. COMPLEMENT INHIBITION
US20240383917A1 (en) 2021-08-18 2024-11-21 Xizang Haisco Pharmaceutical Co., Ltd. Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
EP4398906A1 (en) 2021-09-07 2024-07-17 Novartis AG Use of factor b inhibitors for the treatment of age-related macular degeneration
US20250243186A1 (en) * 2021-10-27 2025-07-31 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
MX2024009062A (es) 2022-01-24 2024-07-29 Novartis Ag Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.
CA3242815A1 (en) 2022-01-26 2023-08-03 Shanghai Meiyue Biotech Dev Co Ltd SALT FORM AND CRYSTAL FORM OF COMPLEMENT FACTOR B INHIBITOR, CORRESPONDING PREPARATION METHOD AND ASSOCIATED USE
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
IL314494A (en) 2022-03-04 2024-09-01 Novartis Ag Use of iptacopan for the treatment of lupus nephritis
US20250223277A1 (en) 2022-04-01 2025-07-10 Novartis Ag Complement factor b inhibitors and uses thereof
CN119698414A (zh) * 2022-06-20 2025-03-25 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
WO2023246870A1 (zh) * 2022-06-23 2023-12-28 上海济煜医药科技有限公司 吲哚化合物的制备、应用及用途
CN119403797A (zh) 2022-06-30 2025-02-07 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的可药用盐、晶型及其制备方法
AU2023335519A1 (en) * 2022-08-29 2025-04-03 Cms Research & Development Pte. Ltd. Series of nitrogen-containing bridged heterocyclic compounds and preparation method therefor
TW202423426A (zh) * 2022-08-31 2024-06-16 美商奇努克醫療股份有限公司 經取代之吲哚化合物及其使用方法
JP2025530222A (ja) 2022-09-10 2025-09-11 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ２－置換ピペリジン誘導体、その製造方法及び医薬的用途
CN118026998A (zh) 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
WO2024104292A1 (en) * 2022-11-14 2024-05-23 Novartis Pharma Ag Solid forms of complement factor b inhibitors
WO2024114677A1 (zh) * 2022-11-29 2024-06-06 上海济煜医药科技有限公司 苯并螺环吲哚化合物的制备、应用及用途
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用
WO2024148274A1 (en) * 2023-01-05 2024-07-11 Apellis Pharmaceuticals, Inc. Complement inhibition
TW202434240A (zh) * 2023-02-22 2024-09-01 大陸商西藏海思科製藥有限公司 苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用
IL322259A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of using factor b inhibitors
CN118684668A (zh) * 2023-03-21 2024-09-24 上海美悦生物科技发展有限公司 螺环类化合物及其药物组合物、制备方法和用途
WO2024222852A1 (zh) 2023-04-27 2024-10-31 上海翰森生物医药科技有限公司 一种哌啶基吲哚化合物的盐及其制备方法
WO2025008451A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
WO2025008453A1 (en) 2023-07-04 2025-01-09 Sitala Bio Ltd 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
WO2025008517A1 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Indole derivatives with factor b inhibitory activity
WO2025008516A2 (en) 2023-07-06 2025-01-09 Sitala Bio Ltd Novel compounds
WO2025021158A1 (zh) * 2023-07-26 2025-01-30 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
WO2025046421A1 (en) 2023-08-25 2025-03-06 Novartis Ag Methods of using factor b inhibitors
AR133953A1 (es) 2023-09-29 2025-11-19 Novartis Ag Inhibidores del factor b del complemento y usos de los mismos
WO2025083621A1 (en) 2023-10-20 2025-04-24 Novartis Ag Treatment of hidradenitis suppurativa using anti-baff-r antibodies
TW202535375A (zh) * 2023-12-05 2025-09-16 大陸商西藏海思科製藥有限公司 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途
WO2025148628A1 (zh) * 2024-01-10 2025-07-17 河北以岭医药研究院有限公司 哌啶基吲哚衍生物及其制备方法和应用
WO2025172535A1 (en) 2024-02-15 2025-08-21 Sitala Bio Ltd Indole and benzimidazole compounds as factor b inhibitors
TW202533829A (zh) 2024-02-16 2025-09-01 瑞士商諾華公司 用於治療anca相關性血管炎的因子b抑制劑
WO2025185734A1 (zh) * 2024-03-08 2025-09-12 江苏豪森药业集团有限公司 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
WO2025237237A1 (en) * 2024-05-11 2025-11-20 Alebund Pharmaceuticals (Hong Kong) Limited Complement factor b inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
DE10237723A1 (de) * 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
HRP20050559A2 (en) 2002-12-19 2006-02-28 Pfizer Inc. 2-(1h-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7524878B2 (en) 2003-04-30 2009-04-28 The Institute For Pharmaceuticals Discovery Llc Phenyl substituted carboxylic acids
AU2005307818A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors
JP2008530018A (ja) * 2005-02-08 2008-08-07 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼ阻害剤
US20100197657A1 (en) 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
ES2759751T3 (es) 2009-07-14 2020-05-12 Nerviano Medical Sciences Srl 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamidas
EP3064204A1 (en) 2010-03-01 2016-09-07 GTx, Inc. Compounds for treatment of cancer
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
BR112013017316A2 (pt) * 2011-01-04 2019-09-24 Novartis Ag compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
HK1206017A1 (en) * 2012-05-04 2015-12-31 Novartis Ag Complement pathway modulators and uses thereof
WO2013192345A1 (en) * 2012-06-20 2013-12-27 Novartis Ag Complement pathway modulators and uses thereof
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b

Also Published As

Publication number Publication date
US9682968B2 (en) 2017-06-20
CN105579444B (zh) 2018-05-01
KR20160030556A (ko) 2016-03-18
SI3022192T1 (en) 2018-01-31
EP3022192A1 (en) 2016-05-25
HUS2400034I1 (hu) 2024-10-28
PL3022192T3 (pl) 2018-03-30
PE20161066A1 (es) 2016-10-30
LTPA2024526I1 (enExample) 2024-10-10
LT3022192T (lt) 2017-12-27
NZ715780A (en) 2021-03-26
FR24C1036I1 (fr) 2024-12-06
ES2655855T3 (es) 2018-02-21
JP6378761B2 (ja) 2018-08-22
UY35663A (es) 2015-02-27
NL301292I2 (nl) 2024-10-30
AP2016008992A0 (en) 2016-01-31
CA2917839A1 (en) 2015-01-22
MX351291B (es) 2017-10-09
CU24397B1 (es) 2019-04-04
US20160152605A1 (en) 2016-06-02
WO2015009616A1 (en) 2015-01-22
UA117371C2 (uk) 2018-07-25
EA201690223A1 (ru) 2016-06-30
JP2016526576A (ja) 2016-09-05
HRP20172000T1 (hr) 2018-02-09
TN2016000017A1 (en) 2017-07-05
KR102242742B1 (ko) 2021-04-23
CY2024027I1 (el) 2025-09-26
SG11201600086PA (en) 2016-02-26
DK3022192T3 (en) 2018-01-22
CL2016000060A1 (es) 2016-06-10
TW201546058A (zh) 2015-12-16
MY187454A (en) 2021-09-22
NO2024042I1 (no) 2024-09-30
IL268623A (en) 2019-10-31
HK1221217A1 (en) 2017-05-26
CN105579444A (zh) 2016-05-11
EA031030B1 (ru) 2018-11-30
CY1119767T1 (el) 2018-06-27
US20180009795A1 (en) 2018-01-11
IL243540B (en) 2019-09-26
EP3299365A1 (en) 2018-03-28
BR112016000909B1 (pt) 2023-05-02
AU2014290298B2 (en) 2017-06-15
BR112016000909A2 (pt) 2017-07-25
JO3425B1 (ar) 2019-10-20
GT201600007A (es) 2018-12-18
PT3022192T (pt) 2018-01-15
FR24C1036I2 (fr) 2025-08-01
US10093663B2 (en) 2018-10-09
FIC20240032I1 (fi) 2024-10-01
HUE037510T2 (hu) 2018-09-28
TWI641600B (zh) 2018-11-21
AU2014290298A1 (en) 2016-02-11
MY196427A (en) 2023-04-10
CY2024027I2 (el) 2025-09-26
ES2655855T4 (es) 2024-09-06
CU20160006A7 (es) 2016-08-31
EP3022192B1 (en) 2017-10-11
SV2016005137A (es) 2018-06-12
PH12016500072A1 (en) 2016-04-18
IL268623B (en) 2020-01-30
PH12016500072B1 (en) 2016-04-18
CA2917839C (en) 2022-05-03
IL243540A0 (en) 2016-02-29
BR112016000909A8 (pt) 2020-01-07

Similar Documents

Publication Publication Date Title
US10093663B2 (en) Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof
JP6209605B2 (ja) ピロリジン誘導体、および補体経路調節因子としてのその使用
JP6238980B2 (ja) 補体経路モジュレーターおよびその使用
JP6154897B2 (ja) ピロリジン誘導体、および補体経路調節因子としてのその使用
US9815819B2 (en) Complement pathway modulators and uses thereof
JP6387391B2 (ja) 眼科疾患の処置に有用な補体因子Ｂ阻害剤としての２−（１Ｈ−インドール−４−イルメチル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−６−カルボニトリル誘導体
JP2015522007A (ja) ピロリジン誘導体、および補体経路モジュレーターとしてのその使用
HK1221217B (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
NZ715780B2 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
NZ754317B2 (en) Piperidinyl indole derivatives and their use as complement Factor B inhibitors
NZ754317A (en) Piperidinyl indole derivatives and their use as complement Factor B inhibitors